Intellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $13.00 at Robert W. Baird

Intellia Therapeutics (NASDAQ:NTLA) had its price target upped by Robert W. Baird from $7.00 to $13.00 in a research note issued to investors on Monday morning, Marketbeat reports. Robert W. Baird currently has a neutral rating on the stock.

A number of other equities research analysts also recently weighed in on the stock. Bank of America reissued a “neutral” rating on shares of Intellia Therapeutics in a research note on Monday, March 2nd. JonesTrading raised shares of Intellia Therapeutics from a “hold” rating to a “buy” rating and set a $29.00 target price for the company in a report on Wednesday, March 4th. William Blair upgraded shares of Intellia Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Monday, March 2nd. Wells Fargo & Company increased their price target on Intellia Therapeutics from $12.00 to $15.00 and gave the company an “equal weight” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Intellia Therapeutics in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, nine have assigned a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $20.05.

Intellia Therapeutics Stock Down 4.5%

Shares of NTLA opened at $13.01 on Monday. The stock’s fifty day simple moving average is $13.59 and its 200-day simple moving average is $12.89. The firm has a market capitalization of $1.54 billion, a PE ratio of -3.40 and a beta of 1.99. Intellia Therapeutics has a 12-month low of $6.83 and a 12-month high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.83) earnings per share for the quarter, topping the consensus estimate of ($0.99) by $0.16. Intellia Therapeutics had a negative return on equity of 56.81% and a negative net margin of 609.85%.The firm had revenue of $23.02 million during the quarter, compared to analysts’ expectations of $12.17 million. During the same period in the previous year, the business posted ($1.27) EPS. The company’s quarterly revenue was up 78.4% compared to the same quarter last year. Analysts anticipate that Intellia Therapeutics will post -3.53 EPS for the current year.

Hedge Funds Weigh In On Intellia Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Comerica Bank increased its position in shares of Intellia Therapeutics by 45.8% in the 4th quarter. Comerica Bank now owns 2,869 shares of the company’s stock valued at $26,000 after buying an additional 901 shares in the last quarter. Headlands Technologies LLC acquired a new position in Intellia Therapeutics in the second quarter valued at about $26,000. Blue Bell Private Wealth Management LLC bought a new stake in shares of Intellia Therapeutics in the third quarter worth about $30,000. Caitong International Asset Management Co. Ltd bought a new stake in shares of Intellia Therapeutics in the third quarter worth about $30,000. Finally, Advisory Services Network LLC acquired a new stake in shares of Intellia Therapeutics during the third quarter worth about $33,000. Institutional investors and hedge funds own 88.77% of the company’s stock.

Key Stories Impacting Intellia Therapeutics

Here are the key news stories impacting Intellia Therapeutics this week:

• Positive Sentiment: Intellia reported positive topline Phase 3 HAELO results for lonvoguran (ziclumeran) that met the primary and all key secondary endpoints and showed favorable safety — a potential first-ever one-time in‑vivo gene‑editing therapy for HAE, a major clinical milestone. Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema
• Positive Sentiment: Intellia initiated a rolling BLA submission to the FDA for lonvo‑z and provided a first‑half‑2027 U.S. launch expectation if approved — a clear path to commercialization that materially derisks program timing. Intellia Initiates Rolling Submission of BLA to FDA for Lonvoguran
• Positive Sentiment: Major media and wire coverage (Reuters, CNBC) highlighted the Phase 3 success as a landmark for in‑vivo CRISPR therapy, boosting investor interest and helping premarket rallies. Reuters: Intellia therapy meets main goal in trial
• Positive Sentiment: Analyst support and call buying: Chardan raised its price target to $30 (buy) and there was unusual call activity (nearly double typical call volume), signaling bullish speculation around the program. Benzinga / The Fly: Price target and options
• Neutral Sentiment: Robert W. Baird raised its target to $13 and kept a neutral rating — this is a mild endorsement but less bullish than Chardan’s view, reflecting some investor caution on commercialization and valuation. Benzinga: Baird raises target
• Neutral Sentiment: Coverage pieces noting “why shares aren’t flying” provide context: investors are weighing one‑time curative potential against commercial, regulatory and manufacturing unknowns — explains a muted or mixed price response despite big clinical news. MSN: Why shares aren’t flying
• Negative Sentiment: Intellia announced a $150M underwritten public offering (plus a 15% overallotment option). New share issuance is dilutive and often puts short‑term pressure on the stock despite positive clinical news. GlobeNewswire: Proposed public offering
• Negative Sentiment: Despite the favorable trial, several outlets reported intraday selling/stock declines — likely profit‑taking, dilution worries from the offering, and investors locking gains after a big premarket pop. Investing.com: Stock falls despite positive results

About Intellia Therapeutics

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.